Kayothera
  • Science
  • Team
  • Investors
  • News
  • Contact
Select Page
Kayothera, Inc. Nominates KAYO-1732, a First-In-Class, Oral Inhibitor of the Retinoid Nuclear Receptor Pathway in Type 2 Diabetes and Cardiometabolic Indications as a Development Candidate

Kayothera, Inc. Nominates KAYO-1732, a First-In-Class, Oral Inhibitor of the Retinoid Nuclear Receptor Pathway in Type 2 Diabetes and Cardiometabolic Indications as a Development Candidate

Sep 23, 2025 | News, Press Release

Seattle, WA — September 23, 2025 – Kayothera, Inc. (“Kayothera”), a preclinical therapeutics company developing first-in-class, small molecule inhibitors of the retinoid nuclear receptor pathway, today announces that it has selected KAYO-1732 as a drug development...
Kayothera, Inc. Nominates KAYO-1732, a First-In-Class, Oral Inhibitor of the Retinoid Nuclear Receptor Pathway in Type 2 Diabetes and Cardiometabolic Indications as a Development Candidate

Kayothera Named as a Winner of the American Diabetes Association’s Innovation Challenge to Transform Type 2 Diabetes Care

Jun 21, 2025 | News, Press Release

Seattle, WA — June 21, 2025, Kayothera, Inc., a preclinical-stage therapeutics company pioneering first-in-class, oral inhibitors of the retinoid nuclear receptor pathway, today announced that it has been recognized as one of the winners of the American Diabetes...
Kayothera, Inc. Nominates KAYO-1732, a First-In-Class, Oral Inhibitor of the Retinoid Nuclear Receptor Pathway in Type 2 Diabetes and Cardiometabolic Indications as a Development Candidate

Kayothera Announces Expansion of the Scientific Advisory Board

Oct 22, 2024 | News, Press Release

Yibin Kang, PhD, chairs Scientific Advisory Board that includes experts in translational and early-phase clinical development activities Seattle, WA — October 22, 2024, Kayothera, Inc., a preclinical-stage therapeutics company developing first-in-class, oral, small...
Kayothera, Inc. Nominates KAYO-1732, a First-In-Class, Oral Inhibitor of the Retinoid Nuclear Receptor Pathway in Type 2 Diabetes and Cardiometabolic Indications as a Development Candidate

Kayothera Announces New Appointments to Board of Directors

Oct 14, 2024 | News, Press Release

Bruce L.A. Carter, PhD, and Paul Sekhri join Board of Directors, adding drug development and operating experience Recent board additions highlight Kayothera’s evolution into pipeline-focused organization with meaningful translational efforts Seattle, WA —...
The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes

The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes

Aug 12, 2024 | News

Review | Cancer Focus| August 12 2024 In Special Collection: Mechanisms and Models of Cancer 2024 Mark Esposito, John K. Amory, Yibin Kang J Exp Med (2024) 221 (9): e20240519. https://doi.org/10.1084/jem.20240519
Join us at BioNJ BioPartnering

Join us at BioNJ BioPartnering

Apr 3, 2024 | Events, News

Join our Co-Founder Dr. Mark Esposito as he shares an update on Kayothera at BioNJ BioPartnering on May 14th.
« Older Entries

Categories

  • Events (2)
  • News (22)
  • Press Release (8)
  • Contact
    © 2024 KAYOTHERA® — All Rights Reserved